Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status Prescription; Discontinued
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 25000-012; 70121-1036; 65862-938; 68382-331; 68513-1054; 25000-014; 66499-0019; 0409-1008; 63629-2452; 69452-145; 17478-033; 25000-017; 10888-8103; 0143-9625; 67457-692; 70121-1035; 49483-687; 43598-563; 55150-213; 48943-0033; 58032-1001; 55111-663; 70121-1034; 69452-146; 65862-937; 55150-214; 68382-330; 0143-9624; 11014-0053; 43598-564; 43598-565; 43598-562; 0074-9036; 55111-665; 63629-2453; 0074-1658; 55150-212; 10888-8102; 55150-215; 65162-822; 58272-192; 49483-689; 0409-1007; 65162-824; 49483-688; 65162-823; 55111-664; 69452-147; 11014-0048; 16729-310; 0074-9037; 16729-311; 70121-1033; 67457-380; 65862-936; 10888-8104; 0143-9596; 0074-4637; 14474-021
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Adverse drug reactionAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
Electrolyte imbalanceGastrin/cholecystokinin type B receptorP32239T0584912529809; 12073167; 9160584; 7619662
Iron and trace metal metabolism disordersParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Iron and trace metal metabolism disordersAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Ear disorder04.03.01.001--Not Available
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
Encephalopathy17.13.02.001--
Endocarditis11.01.16.001; 02.09.01.0010.005865%
Endocrine disorder05.09.01.001--Not Available
Endophthalmitis11.01.06.003; 06.04.05.009--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Eye disorder06.08.03.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fluid overload14.05.06.001; 02.05.04.004--Not Available
Fungal infection11.03.05.001--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
Gangrene24.04.05.003; 23.06.06.001; 11.02.01.0030.002346%Not Available
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal carcinoma16.13.04.001; 07.21.03.0010.003519%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Glaucoma06.03.01.002--
Haematuria20.02.01.006; 24.07.01.047--
Haemoglobin decreased13.01.05.003--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages